BioSpace News Archive

Gritstone bio, Inc. today announced the appointment of Stephen Webster to its Board of Directors.

Bio-Techne Corporation is pleased to announce a significant milestone in its commitment to providing cutting-edge solutions to its customers.

Deciphera Pharmaceuticals, Inc. today announced that it has entered into a definitive merger agreement with ONO Pharmaceutical Co., Ltd.

Alterity Therapeutics today announced that important new data on its lead drug candidate ATH434 was presented at the World Orphan Drug Congress USA 2024 in Boston.

Onco360 has been selected as a pharmacy partner by Day One Biopharmaceuticals for OJEMDA™ (tovorafenib), which is now FDA approved for the treatment of patients six months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.

Cognition Therapeutics, Inc. today announced that the company has reached target enrollment in the randomized, placebo-controlled Phase 2 SHIMMER (COG1201) study (NCT05225415 ), which is examining the safety and effectiveness of CT1812 in adults with mild-to-moderate dementia with Lewy bodies (DLB).

Immunovia today announces the appointment of Dr. Lisa Ford as Clinical Laboratory Director.

Bitterroot Bio today announced that the first human participants have been dosed in a Phase 1 study of BRB-002 in healthy volunteers.

Pasithea Therapeutics Corp. today announced the acceptance of an abstract for poster presentation at the American Society of Cancer Oncology (“ASCO”), which will be held in Chicago from May 31 – June 4, 2024.

Collegium Pharmaceutical, Inc. today announced it has entered into an authorized generic agreement with Hikma Pharmaceuticals USA Inc. (“Hikma”), pursuant to which Hikma will have the exclusive right to sell the authorized generic versions of Nucynta® and Nucynta ® ER.